The long-term (mean follow up, 51 weeks) efficacy of cw Nd:YAG laser t
rabeculoplasty in reducing intraocular pressure (IOP) was studied in 1
06 eyes of 75 patients. Fifty patients (73 eyes) of this group had pri
mary open-angle glaucoma; 11 (17), mixed glaucoma; 10 (12), pseudoexfo
liation syndrome; and 4 (4), secondary glaucoma of varied etiology. Fi
fty laser impacts were delivered over 180-degrees of the circumference
of the chamber angle with an Nd:YAG laser working in the cw mode (spo
t diameter, 100 mum; exposure duration, from 200 to 300 milliseconds;
constant power level, 9 W, resulting in 1.8 to 2.7 J/pulse and a total
energy dose/session of 90 to 135 J). In a few cases, an exposure dura
tion of 400 milliseconds was used, corresponding to a pulse energy of
3.6 J/pulse and a total energy dose/session of 180 J. Success was defi
ned as a reduction in IOP to 22 mm Hg or less without any further lase
r or surgical intervention. The cumulative success rate was 97.2% at 1
month, 93.3% at 3 months, 83.3% at 6 months, 78.7% at 12 months, and
71.5% at 24 months. Thus, the efficacy of cw Nd:YAG laser trabeculopla
sty is comparable to that reported for trabeculoplasty performed using
the argon laser (ALT), the Nd:YAG laser working in the free-running m
ode, and the diode laser. Biomicroscopy failed to reveal any serious i
nflammatory reactions persisting longer than 1 week. We conclude that
cw Nd:YAG laser trabeculoplasty is a safe and effective alternative to
ALT.